BiotechTube

Denosumab + Placebo + Alendronate sodium hydrate

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteoporosis

Conditions

Osteoporosis

Trial Timeline

May 1, 2008 → Jul 1, 2012

NCT ID
NCT00680953

About Denosumab + Placebo + Alendronate sodium hydrate

Denosumab + Placebo + Alendronate sodium hydrate is a phase 3 stage product being developed by Daiichi Sankyo for Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00680953. Target conditions include Osteoporosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00680953Phase 3Completed

Competing Products

20 competing products in Osteoporosis

See all competitors
ProductCompanyStageHype Score
ENZ215 + ProliaAlkem LaboratoriesPhase 3
77
Teriparatide + Alendronate Sodium + Placebo + PlaceboEli LillyPhase 3
77
TeriparatideEli LillyPhase 3
77
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
77
raloxifene + PlaceboEli LillyApproved
85
Subcutaneous Teriparatide + Transdermal TeriparatideEli LillyPhase 2
52
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
raloxifene + placeboEli LillyApproved
85
Teriparatide + Salmon CalcitoninEli LillyPhase 3
77
ForteoEli LillyPre-clinical
23
arzoxifene + PlaceboEli LillyPhase 2
52
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
CT-P41 + US-licensed ProliaCelltrionPhase 3
77
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboChugai PharmaceuticalPhase 3
77
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
23
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
77
YM529 / ONO-5920Astellas PharmaPhase 2/3
65
ONO-5920Astellas PharmaPhase 3
77
Minodronic acid hydrateAstellas PharmaPhase 3
77
ONO-5920 / YM529Astellas PharmaPhase 1
33

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85